Exchange Traded Concepts’s Terns Pharmaceuticals TERN Stock Holding History

Exchange Traded Concepts’s Portfolio TERN Stock Details TERN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-121,455	Closed	-$912K	–	1640
2025 Q3	$912K	Sell	121,455 -106,392	-47%	-$679K	0.01%	806
2025 Q2	$850K	Buy	227,847 +90,184	+66%	+$282K	0.01%	739
2025 Q1	$380K	Sell	137,663 -5,256	-4%	-$21.5K	0.01%	814
2024 Q4	$792K	Buy	142,919 +36,363	+34%	+$246K	0.02%	664
2024 Q3	$889K	Buy	106,556 +7,784	+8%	+$64K	0.02%	561
2024 Q2	$673K	Buy	+98,772	New	+$598K	0.02%	587

Other funds holding TERN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

CLGM

Capitolis Liquid Global Markets New York $15.7B AUM 30.78% 1-Year Est. Return

Exchange Traded Concepts's TERN Position: Q4 2025 in Review

Exchange Traded Concepts sold out of Terns Pharmaceuticals (TERN) in Q4 2025, closing a stake of 121,455 shares — an estimated $912K sold.

Exchange Traded Concepts first reported a position in TERN in Q2 2024 and held it in 6 quarters. The position peaked at $912K in Q3 2025. 248 funds tracked by Wall St. Rank hold TERN as of Q4 2025.

Exchange Traded Concepts reported no remaining Terns Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Exchange Traded Concepts sold 121,455 Terns Pharmaceuticals shares in Q4 2025, an estimated $912K.
Exchange Traded Concepts first reported a position in Terns Pharmaceuticals in Q2 2024 and held it in 6 quarters.
Exchange Traded Concepts's Terns Pharmaceuticals position peaked at $912K in Q3 2025.
248 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q4 2025.

Based on Exchange Traded Concepts's 13F filing for Q4 2025, filed 14 Jan 2026.